Repeatability of deuterium metabolic imaging of healthy volunteers at 3 T.
Autor: | Bøgh N; The MR Research Centre, Dept. Of Clinical Medicine, Aarhus University, Palle Juul-Jensens Boulevard 99, Aarhus, Denmark. nikolaj.boegh@clin.au.dk.; A&E, Gødstrup Hospital, Herning, Denmark. nikolaj.boegh@clin.au.dk., Vaeggemose M; The MR Research Centre, Dept. Of Clinical Medicine, Aarhus University, Palle Juul-Jensens Boulevard 99, Aarhus, Denmark.; GE HealthCare, Brondby, Denmark., Schulte RF; GE HealthCare, Munich, Germany., Hansen ESS; The MR Research Centre, Dept. Of Clinical Medicine, Aarhus University, Palle Juul-Jensens Boulevard 99, Aarhus, Denmark., Laustsen C; The MR Research Centre, Dept. Of Clinical Medicine, Aarhus University, Palle Juul-Jensens Boulevard 99, Aarhus, Denmark. |
---|---|
Jazyk: | angličtina |
Zdroj: | European radiology experimental [Eur Radiol Exp] 2024 Mar 13; Vol. 8 (1), pp. 44. Date of Electronic Publication: 2024 Mar 13. |
DOI: | 10.1186/s41747-024-00426-4 |
Abstrakt: | Background: Magnetic resonance (MR) imaging of deuterated glucose, termed deuterium metabolic imaging (DMI), is emerging as a biomarker of pathway-specific glucose metabolism in tumors. DMI is being studied as a useful marker of treatment response in a scan-rescan scenario. This study aims to evaluate the repeatability of brain DMI. Methods: A repeatability study was performed in healthy volunteers from December 2022 to March 2023. The participants consumed 75 g of [6,6'- 2 H Results: Six male participants were recruited, aged 34 ± 6.5 years (mean ± standard deviation). There was 42 ± 2.7 days between sessions. Whole-brain levels of glutamine + glutamate, lactate, and glucose increased to 3.22 ± 0.4 mM, 1.55 ± 0.3 mM, and 3 ± 0.7 mM, respectively. The best signal-to-noise ratio and repeatability was obtained at the 120-min timepoint. Here, the within-subject whole-brain CoVs were -10% for all metabolites, while the between-subject CoVs were -20%. Conclusions: DMI of glucose and its downstream metabolites is feasible and repeatable on a clinical 3 T system. Trial Registration: ClinicalTrials.gov, NCT05402566 , registered the 25th of May 2022. Relevance Statement: Brain deuterium metabolic imaging of healthy volunteers is repeatable and feasible at clinical field strengths, enabling the study of shifts in tumor metabolism associated with treatment response. Key Points: • Deuterium metabolic imaging is an emerging tumor biomarker with unknown repeatability. • The repeatability of deuterium metabolic imaging is on par with FDG-PET. • The study of deuterium metabolic imaging in clinical populations is feasible. (© 2024. The Author(s).) |
Databáze: | MEDLINE |
Externí odkaz: |